GenomOncology is proud to be the exclusive commercial partner of Vanderbilt’s My Cancer Genome, the leading knowledge resource matching tumor mutations to therapies.

GenomOncology is more than user and distributor of My Cancer Genome. We are active science and technology collaborators with the team at Vanderbilt. In fact, the company was selected to develop and deploy the flexible content management system that Vanderbilt now uses to power My Cancer Genome.

To learn more about My Cancer Genome, please visit their website. You are also invited to watch an informative recorded talk by My Cancer Genome’s Mia Levy, MD, PhD, on Guiding Cancer Therapy with My Cancer Genome: Past, Present, and Future.

Guiding Cancer Therapy

In addition to My Cancer Genome, integrated decision support in the GO Precision Medicine Portfolio™ is provided by data derived from FDA, ASCO, and NCCN guidelines.